Custom Report

La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis and assessment reports can be prepared according to the specifications of the client from the pharmaceutical or biotechnology industry.

More info

Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that a £10 million milestone payment from AstraZeneca has been triggered as a result of the successful scale-up of the CytoFab™ manufacturing process to a 600 litre batch size.



LONDON, UK and BRENTWOOD, TN, USA | Mar 12, 2007 | Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that a £10 million milestone payment from AstraZeneca has been triggered as a result of the successful scale-up of the CytoFab™ manufacturing process to a 600 litre batch size. This milestone will be included in the Company’s results for the financial year ending 31 March 2007 and is expected to be received in April.

SOURCE: Protherics PLC

Post Views: 112